Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018740 | 0.86 | RIPK1 (0.73) | RIPK1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL1709361 | 0.85 | RIPK1 (0.71) | RIPK1HPGDKDM4ELMNAKMT2A | |
| SCHEMBL1709321 | 0.84 | RIPK1 (1.00) | RIPK1SMN1; SMN2LMNARAB9AALDH1A1 | |
| SCHEMBL14253969 | 0.84 | HDAC6 (0.65) | RIPK1SMN1; SMN2NPC1HPGDKDM4E | |
| SCHEMBL15965766 | 0.83 | RIPK1 (0.63) | RIPK1HPGDLMNAHDAC6CA1 | |
| SCHEMBL27799310 | 0.82 | RIPK1 (0.67) | RIPK1LMNAHDAC6 | |
| SCHEMBL20221145 | 0.81 | RIPK1 (0.71) | RIPK1SMN1; SMN2LMNARAB9AALDH1A1 | |
| SCHEMBL14566921 | 0.81 | RIPK1 (0.65) | RIPK1HDAC6CA1CA2CA7 | |
| SCHEMBL12169297 | 0.81 | SMN1; SMN2 (0.54) | RIPK1SMN1; SMN2NPC1HPGDKDM4E | |
| SCHEMBL27799295 | 0.80 | RIPK1 (0.63) | RIPK1LMNARAB9AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679457-A | Piperazine and [1,4] diazepane derivatives as NK antagonists | HOFFMANN LA ROCHE | 2010-03-24 | — | — | CN | claimed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20130095429-A1 | ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN USING THE SAME | FUJIFILM CORPORATION (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| CN-101679457-A | Piperazine and [1,4] diazepane derivatives as NK antagonists | HOFFMANN LA ROCHE | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | RIPK1 4263/4885SMN1; SMN2 1774/4885NPC1 1968/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | RIPK1 4263/4885SMN1; SMN2 1774/4885NPC1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.